Identifying Real-World Evidence Gaps in mCSPC Care

Panelists discuss how continued progress in metastatic castration-sensitive prostate cancer (mCSPC) depends on closing current gaps in real-world evidence (RWE) surrounding comparative effectiveness and therapy sequencing. While clinical trials have established the efficacy of androgen receptor pathway inhibitors (ARPIs), real-world data remain limited on how best to transition between therapies once resistance develops or comorbidities evolve. The panel emphasizes that understanding sequencing patterns—especially among diverse patient populations—is essential for optimizing both survival and quality of life.

Panelists discuss how future RWE studies should focus on inclusivity, consistency, and depth of data capture. Broader patient representation—including older adults, racial and ethnic minorities, and those treated in community settings—will improve the generalizability of findings. Standardized outcome measures, such as treatment duration, adherence rates, and patient-reported quality of life, will enhance comparability across studies. The use of integrated data sources—linking electronic health records, pharmacy data, and registries—can also provide a more complete picture of real-world patient journeys and treatment effectiveness.

Panelists discuss how collaboration between academic centers, community practices, and industry partners will accelerate high-quality evidence generation. The integration of advanced analytics and artificial intelligence could uncover new patterns of resistance, treatment success, and sequencing outcomes. Ultimately, bridging current RWE gaps will empower clinicians to make more confident, personalized treatment decisions and ensure that every patient benefits from evidence that reflects the realities of modern prostate cancer care.